Identification of active small-molecule modulators targeting the novel immune checkpoint VISTA
Abstract Background Cancer immunotherapy has gained increasing popularity as a novel approach to treat cancer. A member of the B7 family, V-domain immunoglobulin suppressor of T-cell activation (VISTA) is a novel immune checkpoint that regulates a broad spectrum of immune responses. VISTA is an acid...
Main Authors: | Ting-ting Li, Jing-wei Jiang, Chen-xin Qie, Chun-xiao Xuan, Xin-lei Hu, Wan-mei Liu, Wen-ting Chen, Jun Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-08-01
|
Series: | BMC Immunology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12865-021-00446-4 |
Similar Items
-
Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR
by: Xiuman Zhou, et al.
Published: (2020-09-01) -
Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma
by: Felix C. Popp, et al.
Published: (2021-05-01) -
TSH RECEPTOR SIGNALING ABROGATION BY A NOVEL SMALL MOLECULE
by: Rauf Latif, et al.
Published: (2016-09-01) -
In Silico Screening and In Vivo Evaluation of Potential CACNA2D1 Antagonists as Intraocular Pressure-Reducing Agents in Glaucoma Therapy
by: Hanxuan Li, et al.
Published: (2021-08-01) -
The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma
by: Heike Loeser, et al.
Published: (2019-05-01)